Albrioza (sodium phenylbutyrate;ursodoxicoltaurine)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- sodium phenylbutyrate;ursodoxicoltaurine
- Company
- Amylyx Pharmaceuticals EMEA B.V.
- Status
- Refused
- Therapeutic area
- Amyotrophic Lateral Sclerosis
- CHMP opinion
- Thu 12 Oct 2023
- Designations
- Orphan
- Application
- EMEA/H/C/005901
- ATC
- N07XX
- Official record
- www.ema.europa.eu
Indication
Treatment of amyotrophic lateral sclerosis (ALS)
Regulatory milestones
No milestones recorded in the last year.
Follow Albrioza
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.